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Background: Lung cancer causes impairment of health-related quality of life (QoL), but little is known 
about gender aspects in QoL and symptom burden of lung cancer patients. The aim of this study was to 
investigate gender differences in QoL as assessed by the European Organization for Research and Treatment 
of Cancer (EORTC) QLQ-C30 and the updated lung cancer module. 
Methods: In a prospective, international, cross-cultural, multicenter study that was undertaken to update 
the lung cancer-specific module EORTC QLQ-LC13, patients filled in the core questionnaire EORTC 
QLQ-C30 and the updated lung cancer module. Gender differences were calculated for all QoL scores using 
ANCOVAs that controlled for known and suspected confounders. Comparisons with historic data were 
drawn.
Results: A total of 200 patients (82 female and 118 male, median age 65 years) were recruited. With the 
exception of coughing (estimated marginal means: women 33.86 and men 43.52, P=0.022) and diarrhea 
(estimated marginal means: women 26.01 and men 17.93, P=0.038) there were no significant QoL gender 
differences. Fatigue was the most pronounced symptom in both, men and women, outpacing typical 
respiratory symptoms. Quite generally, our sample of lung cancer patients showed considerably worse QoL 
in all scores when compared to EORTC reference data (lung cancer and combined cancer diagnoses, mean 
differences up to 13.70 and 21.54 score points, respectively) and to a German norm reference sample (up to 
35.37 score points).
Conclusions: This study adds to the literature in showing that the typical QoL gender difference effect 
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Introduction
Gender aspects are becoming an increasingly important 
topic in the treatment of lung diseases. A number of recent 
clinical examples illustrate this point. Lung cancer, one 
of the most common cancers worldwide and the leading 
cause of cancer associated with death (1-3), has witnessed 
a growing incidence in women in recent years (1,4-6). 
Female patients present with more advanced disease stages 
and at a younger age than men, which may be attributable 
to time trends in smoking habits and their related 
effects (1). Adenocarcinoma is the most common type 
of lung cancer in female patients (1,7). Women respond 
better to various therapies in non-small cell lung cancer 
(NSCLC) than men with benefits in overall survival (1,5). 
A Japanese nationwide registry study covering 12,509 
patients showed overall survival benefits for women after 
resection of primary lung neoplasms (5-year survival 
rate of women 75.6% vs. men 57.95%) (7). Women with 
chronic obstructive pulmonary disease (COPD) suffer 
from more exacerbations (8) and greater impairment of 
their health status than men (9). A recent review on asthma 
coined the phrase “the female lung” and came to the 
conclusion that women experience more asthma symptoms 
than men and use more rescue medications, which results 
in reduced quality of life (QoL) (10).
The analysis of gender differences has a long tradition in 
QoL research (11-17). Large-scale studies on representative 
samples conducted in Germany and Norway have 
consistently shown that women report lower levels of QoL 
and higher symptom burden than men as assessed by the 
European Organization for Research and Treatment of 
Cancer (EORTC) QLQ-C30 core questionnaire (11-17). 
This gender effect is relevant with regard to oncological 
therapy, since considerations regarding patients’ QoL 
during and after treatment are becoming a topic of growing 
interest (13,18). For one, QoL contributes to increased 
overall survival (19), for the other improving QoL is a 
treatment goal on its own. In the context of clinical studies it 
has become standard to include QoL measures as endpoint 
variables (20). Therefore, for determining gender differences 
in patients with lung cancer is important to identify areas 
of need for patients and to ensure the best possible clinical 
outcome. 
Lung cancer patients may suffer from numerous 
symptoms, such as dyspnea, coughing, pain and fatigue, 
which have a negative impact on their QoL (4,21). The 
EORTC QLQ-C30 is a well-known questionnaire used 
to assess QoL of cancer patients in oncological clinical 
trials (11). Additionally, as a lung cancer-specific module 
the QLQ-LC13 covers 13 typical symptoms of lung cancer 
patients. It has been used since 1994 together with the 
core questionnaire QLQ-C30 (22). Due to the changes 
in diagnostic and therapeutic options in lung cancer 
treatment, an international multicenter research project has 
been initiated to update the EORTC lung cancer module, 
according to the scientifically acknowledged EORTC 
procedure (20,22). 
In the course of this project data are available that allow 
to investigate gender differences in QoL reporting. The 
goal of the present paper was to analyze whether female and 
male lung cancer patients differ with regard to their self-
reported somatic symptoms and functional QoL outcomes, 
and whether certain symptoms are reported as being more 
intense or more frequent in women than in men. Based on the 
previous findings of large scale studies (11-17), we proceeded 
with the hypothesis that women report worse QoL and more 
intense symptoms than men. We present the following article 
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administration during or shortly after therapy) in order to 
pick up side effects related to the therapy when assessing 
QoL. The study recruitment took place in nine different 
geographical locations (Germany, Great Britain, Italy, 
Israel, Norway, Poland, Spain, Taiwan and Cyprus) 
from February 2014 until February 2015. The study was 
approved by the Ethical Committee of the University of 
Regensburg, Germany (reference number 11-101-0024) 
and by the local ethical committees of the participating 
centers. The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). All patients 
gave their informed consent prior to being enrolled into this 
study. Details of the study methodology have been reported 
earlier (14). The original study protocol was registered with 
clinicaltrials.gov (reference number NCT01434784).
Patients 
The following eligibility criteria applied: histologically 
proven non-small cell lung cancer (NCSLC) or small cell 
lung cancer (SCLC), 18 years of age or older, no previous 
other or recurrent tumor, cognitive and physical ability 
to fill in a questionnaire and written informed consent. 
Patients were excluded from the study if any of the above 
criteria was not fulfilled.
Procedure
Upon being informed about the study and providing written 
consent, patients filled in the paper-and-pencil version 
of the EORTC QLQ-C30 and the updated lung cancer 
module QLQ-LC29 (22). Thereafter, patients participated 
in a structured interview to evaluate the content of the 
questionnaires. Clinical data were recorded by the study 
personnel, using a standardized case report form (CRF).
Questionnaires
The  EORTC QLQ-C30  ( ve r s ion  3 .0 )  i s  a  core 
questionnaire designed for the use in international clinical 
trials and addresses issues relevant for cancer patients of any 
tumor type (24,25). As its name suggests, the questionnaire 
consists of 30 individual items that are aggregated into a 
global quality of life score, five multi-item function scores 
(social, role, physical, cognitive, and emotional functioning), 
three multi-item symptom scores (nausea, pain, fatigue), 
and five single items (diarrhea, constipation, dyspnea, 
appetite loss, insomnia). Items are accompanied by four-
item Likert scales with the response  options labeled (I) “not 
at all”, (II) “a little”, (III) “quite a bit” and (IV) “very much”, 
with the exception of the two global quality of life items 
that are presented with a seven-item Likert scale (1=very 
poor to 7=excellent). According to the EORTC scoring 
manual, linear transformations are applied, resulting into 
scores from 0 to 100 (25). In the case of functional scores 0 
denotes lowest and 100 highest functioning, in the case of 
symptom scales 0 denotes lowest and 100 highest symptom 
burden. 
The updated EORTC lung cancer module consists 
of 29 items (22). The original QLQ-LC13 has been 
preserved (with the exception of one item tapping into pain 
medication) and amended by items assessing therapy-related 
side effects, existential issues and surgery-related symptoms. 
An initial psychometric analysis suggests that the QLQ-
LC29 consists of five multi-item scales (coughing, shortness 
of breath, side effects, fear of progression, surgery-related 
symptoms) and five single items (coughing blood, pain in 
the chest, pain in the shoulder, bodily pain, problems with 
weight loss) (22).
Statistical analyses
Basic descriptive statistics included counts, percentages, 
medians/interquartile ranges (IQR), means and confidence 
intervals. 
Gender differences in all QoL aspects were analyzed 
using univariate (t-test) and multivariable (analyses of 
covariance, ANCOVA) models. ANCOVAs adjusted for the 
following covariates: age, tumor type (NSCLC vs. SCLC), 
therapeutic approach (curative vs. palliative), living partner 
(with vs. without), education (compulsory vs. higher), 
primary therapy (surgery vs. chemo radiation therapy vs. 
targeted therapy), stage (NSCLC stage IV vs. other stages), 
region (English speaking vs. northern vs. southern vs. eastern 
countries) and comorbidity (yes/no). Estimated marginal 
means with corresponding 95%-confidence intervals were 
presented as effect estimates. A P value <0.05 was considered 
as the threshold of statistical significance. Due to the 
exploratory nature of all analyses, corrections for alpha-error 
were not applied. Furthermore, we compared descriptive 
data of our sample with descriptive data of historic controls, 
namely EORTC large scale cancer reference values (21) and 
representative German population values (11). Differences 
between our sample and historic samples were calculated 
using weighted means across men and women. 
We also analyzed age effects on QoL reporting. In 
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accordance with the EORTC reference data manual (15), 
we applied the following age cut-offs: <50, 50–59, 60–69, 
>70 years.
Analyses were performed using the software packages 
SPSS Statistics 23.0 (IBM Corporation, Armonk, NY, USA) 
and SAS 9.4 (SAS Institute, Cary NC).
Results
Patient characteristics 
A total of 200 patients (82 female and 118 male) were 
enrolled (Table 1). Median age was 65 years (range, 39–91 
years). Most patients had advanced disease (NSCLC stage 
IV n=77, 38.5%) and suffered from comorbidities (n=133, 
66.5%). Non-small cell lung cancer was the predominant 
histological type (SCLC 17.5% vs. NSCLC 82.5%). 
Primary treatment at the time of questionnaire completion 
was either surgery (n=58), radio-chemotherapy (n=113) or 
targeted therapy (n=29).
Gender differences regarding functional and symptom scores
Table 2 presents the estimated marginal means (EMM) 
of QoL for women and men and the respective P values. 
Statistically significant differences were found only in two 
scales: cough severity was higher in men (EMM =43.52) 
than in women (EMM =33.86), P=0.022, and diarrhea 
was more pronounced in women (EMM 26.01) than in 
men (EMM 17.93), P=0.038. Other sizeable differences 
were observed with regard to nausea/vomiting (women 
EMM 26.10 and men EMM 18.58, P=0.053) and financial 
difficulties (women EMM 19.92 and men EMM 28.23, 
P=0.066), but the effects just fell short of the conventional 
level of statistical significance. 
Gender differences and intensity of symptoms 
Figure 1 presents the five most prominent symptoms in 
descending order among women and men. Fatigue was 
the most pronounced symptom in women and men (EMM 
51.32 and 51.29, respectively), followed by dyspnea (EMM 
38.88 and EMM 44.70, respectively). Men, more so than 
women, reported higher symptom burden with regard to 
typical sensations related to lung cancer, such as dyspnea 
(EMM 44.70 vs. 38.88), coughing (EMM 43.52 vs. 33.86) 
and shortness of breath (EMM 34.44 vs. 32.99). 
Table 1 Patient characteristics
Characteristics Total (n=200) Women (n=82) Men (n=118)
Age, median [IQR] 65 [57–71] 63.5 [56–69] 65 [58–71]
Smoking status
Non-smoker 26 (13%) 17 (65.4%) 9 (34.5%)
Smoker 42 (21%) 15 (35.7%) 27 (64.3%)
Ex-Smoker 132 (66%) 50 (37.9%) 82 (62.1%)
Disease
SCLC (all stages) 35 (17.5%) 18 (22.0%) 17 (14.4%)
NSCLC (all stages) 165 (82.5%)  64 (78%) 101 (85.6%)
Therapeutic approach
Curative 88 (44%) 35 (39.8%) 53 (60.2%)
Palliative 112 (56%) 47 (42.0%) 65 (58.0%)
Comorbidity
Yes 133 (66.5%) 49 (36.8%) 84 (63.2%)
No 67 (33.5%) 33 (49.3%) 34 (50.7%)
Karnofsky performance status, median (IQR) 80% (70–90%) 80% (70–90%) 80% (70–90%)
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Comparisons with reference values
Table 2 depicts the original results of our study broken down 
by women and men, as well as historic QoL reference values 
(11,21). 
The EORTC reference value manual contains QoL 
data from 9,028 female and 13,225 male patients pooled 
from numerous international studies with diverse cancer 
diagnoses (brain, breast, colorectal, gastric, genitourinary, 
gynecological, head and neck, leukemia, liver/bile/
pancreas, lung, malignant lymphoma, malignant melanoma, 
mesothelioma, myeloma,  non-Hodgkin lymphoma, 
esophageal, prostate, testicular) (15). 
Table 2 reveals that our sample has higher symptom 
burden/worse functional QoL values than the EORTC 
lung cancer reference sample, particularly in the areas of 
diarrhea (mean difference between samples =13.70), nausea/
vomiting (mean difference =10.87), social functioning 
(mean difference =−10.79), and physical functioning (mean 
difference =−10.38). Even more differences emerge with 
regard to the entire sample of cancer patients. 
The highest differences were observed in comparison 
to the German reference data from a normal population. 
The most striking differences are found regarding role 
functioning (mean difference between samples =−35.37), 
fatigue (mean difference =34.21), dyspnea (mean difference 
=34.21), and social functioning (mean difference =−30.73). 
All reported mean differences between samples 
considerably exceeded 10 score points, a commonly 
accepted criterion for a clinically meaningful difference (15). 
Additional analyses
The gender differences observed with regard to diarrhea 
and coughing triggered additional subgroup analyses. 
We compared the use of targeted therapy (which would 
explain differences in diarrhea) between women and men. 
It turned out that women (18/29, 62.1%) received targeted 
therapy more frequently than men (11/29, 37.9%), 
chi2 =6.22, P=0.013, which corresponds with differences in 
diarrhea.
Furthermore, we calculated gender differences in 
smoking. Men are more likely to have a smoking history 
(either actual smokers or ex-smokers), with the proportion 
of non-smokers being lower (9/118, 7.6%) than in women 
(17/82, 20.7%) chi2 =6.22, P=0.025. Consequently, the 
number of packyears was higher in men (mean rank =96.76) 
than in women (mean rank =66.38), Mann-Whitney 
U =4.56, P<0.001. This corresponds with the higher self-
reported coughing among men.
We also analyzed age effects on QoL reporting, since 
age is consistently and inversely (higher age, lower QoL) 
associated with QoL (11-17). There was not a single 
difference that approached statistical significance. A 
marginal and clinically plausible difference was obtained 
with regard to physical functioning with means being 
(P=0.069). 
Discussion
Gender differences have been a subject of many analyses 
in QoL research (11-17). Based on a number of published 
large-scale studies we started with the notion that women 
would show lower levels of QoL (or, in reverse, higher 
symptom burden) than men. 
In contrast to this hypothesis, we observed only one 
statistically significant difference to the disadvantage of 
women (diarrhea), whereas men reported significantly 
more coughing. This is at odds with other studies showing 
that women with lung cancer coughed significantly more 
than men (26,27). Subanalyses may help to explain these 
Figure 1 Most common symptoms among women (A) and men (B) (intensity of symptoms in descending order among women and men). 
Symptom scales range from 0 (lowest) to 100 (highest) with a higher score denoting higher symptom burden.
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findings: women were more likely to receive targeted 
therapy, and targeted therapy, in turn, is associated with 
heightened levels of diarrhea (28). In our sample, most men 
were smokers and ex-smokers and had a higher number 
of packyears than women, which is a plausible precursor 
of coughing. However, coughing remains a symptom that 
is underresearched and poorly understood in the context 
of lung cancer. Other observational studies have failed to 
demonstrate an association with smoking (27). Further 
research is required in this area.
All other differences in functional and symptom scores 
were statistically not significant. Only one other study is in 
line with our results. In this study of 249 patients who had 
undergone lung surgery, no significant gender-associated 
difference in QoL was demonstrated (29).
Large scale population-based studies consistently 
reported gender differences. An investigation on the QoL 
of the general German population using the EORTC 
QLQ-C30 found that men reported consistently better 
functioning and less symptoms than women (11), and 
these findings were confirmed in a follow-up study (13). 
Population-based studies in Norway, Sweden and The 
Netherlands came to the same conclusion (14,16).
A Swedish population study on elderly cancer patients 
found that women reported more loneliness and fear than 
men (30). These population-based findings are echoed 
by an American NSCLC patient study, showing that men 
reported better QoL 12 weeks later after receiving early 
palliative care than women (31). 
When it comes to the most common symptoms of 
lung cancer patients, earlier studies suggested tumor site-
specific symptoms such as dyspnea, coughing, hemoptysis 
and pain (4,32). The present analysis portrayed a different 
picture; irrespective of gender, the number one symptom 
was fatigue. This is an important finding, since fatigue is 
increasingly being recognized as an unmet need of cancer 
patients (33). Cancer-related fatigue can occur at any time, 
at diagnosis, during treatment or even after treatment and is 
not only a burden on its own but is also associated with an 
increase in mortality (34,35). 
A particularly striking finding is the difference in QoL 
scores of our sample of patients and reference data. Our 
patients report much worse QoL scores than the EORTC 
reference sample of lung cancer patients and even worse 
than a reference sample representing various cancer 
diagnoses. Even more pronounced are differences between 
our sample and data obtained in a German norm data 
survey. This pattern of result might help to explain the lack 
of gender differences: the reduced variation of QoL scores 
in our sample made the detection of group differences 
between women and men less likely. 
The present analysis has several limitations. First, the 
study was not designed to detect gender differences; it was 
originally conducted to revise the EORTC questionnaire 
for QoL of lung cancer patients. Second, experience 
suggests that patients with advanced stages are less likely 
to complete questionnaires. Therefore, a specific gender 
difference study would require well-defined inclusion/
exclusion criteria, allowing for the recruitment of patients 
across a wide range of disease and performance states, as 
well as an appropriate power calculation. 
Conclusions
The present study adds to the literature in showing that 
the typical gender difference effect on QoL (women doing 
worse than men) may not be a universal phenomenon. 
Future studies have to show whether this lack in gender 
differences can be replicated, and whether it is due to 
considerable impairments in QoL, as may have been the 
case in our sample of patients with lung cancer undergoing 
treatment.
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